Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061646 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00061646 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 25 participants.
The verdict
NCT00061646, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
Interventions
- DRUG ABT-510/Thrombospondin-1 mimetic
- DRUG Carboplatin/Taxol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061646
The ClinicalTrials.gov registry entry for NCT00061646 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-510/Thrombospondin-1 mimetic is the first listed.
NCT00061646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061646 about?
NCT00061646 is a clinical study titled "Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)". The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
What is the current status of trial NCT00061646?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00061646?
The interventions under investigation include: ABT-510/Thrombospondin-1 mimetic (DRUG), Carboplatin/Taxol (DRUG).
Who is sponsoring clinical trial NCT00061646?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.